Articles related to ULCERATIVE COLITIS (UC)

Continuous mirikizumab treatment demonstrated durable efficacy across multiple outcome measures for over three years, with 70.1% of week-52 remitters maintaining clinical remission at week 152 and comparable quality of life improvements in both biologic-naïve and biologic-failure patients.

This study’s findings challenge existing understanding by revealing an inverse relationship between ulcerative colitis and bipolar disorder in young adult inpatients. The results, based on a vast sample size and national representation, call for further research to uncover the underlying mechanisms and potential therapeutic implications.

Pioneering research from the Malaghan Institute reveals the potential of hookworm therapy for patients in remission from ulcerative colitis, suggesting a path towards medication-free disease management—learn more about these groundbreaking findings.

Five-hundred thirty-five (535) digitalized biopsies were graded against three standard indexes. A neural network was trained to distinguish remission from activity. The model predicted endoscopic-verified remission or activity with approximately 80% accuracy.

A young woman with ulcerative colitis in remission on 5-ASA and azathioprine is seen for annual follow up. Immunizations are current and her depression and anxiety screens are negative. Review her current status and select the most important health maintenance screen.

As a TROP-2-directed antibody-drug conjugate with an SN-38 payload that has shown preliminary activity in metastatic urothelial carcinoma (mUC), sacituzumab govitecan (SG) – brand name Trodelvy –was evaluated and compared to current treatments to gauge whether SG objective response rates (ORRs) and median overall survival (OS) outperform the average of 10% ORR and 7 to 8 months OS.